Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker RCKT
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Sarbani Chaudhuri See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 4,872 | $2.33 | $11.3K Sale | Form 4 ↗ |
| Nov 5, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 53,389 | $2.39 | $127.8K Sale | Form 4 ↗ |
| Sep 11, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 75,364 | $3.40 | $256.2K Sale | Form 4 ↗ |
| Aug 18, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 631 | $3.38 | $2,133 Sale | Form 4 ↗ |
| Aug 18, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 2,293 | $3.38 | $7,750 Sale | Form 4 ↗ |
| Aug 13, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 2,837 | $3.38 | $9,589 Sale | Form 4 ↗ |
| Aug 13, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 3,493 | $3.38 | $11.8K Sale | Form 4 ↗ |
| Aug 11, 2026 | Christopher James Stevens Chief Operating Officer | RCKT Rocket Pharmaceuticals, Inc. | Sale | 36,658 | $3.50 | $128.3K Sale | Form 4 ↗ |
| Aug 11, 2026 | Sarbani Chaudhuri See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 4,701 | $3.50 | $16.5K Sale | Form 4 ↗ |
| May 21, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 55,684 | $3.09 | $172.1K Sale | Form 4 ↗ |
| May 19, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 2,409 | $3.01 | $7,251 Sale | Form 4 ↗ |
| May 19, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 662 | $3.01 | $1,993 Sale | Form 4 ↗ |
| May 19, 2026 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 384 | $3.01 | $1,156 Sale | Form 4 ↗ |
| May 13, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 3,361 | $3.61 | $12.1K Sale | Form 4 ↗ |
| May 13, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 2,728 | $3.61 | $9,848 Sale | Form 4 ↗ |
| May 13, 2026 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 855 | $3.61 | $3,087 Sale | Form 4 ↗ |
| May 7, 2026 | Sarbani Chaudhuri See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 17,650 | $3.84 | $67.8K Sale | Form 4 ↗ |
| Feb 18, 2026 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,157 | $3.34 | $3,864 Sale | Form 4 ↗ |
| Feb 18, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 5,990 | $3.34 | $20.0K Sale | Form 4 ↗ |
| Feb 18, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,376 | $3.34 | $4,596 Sale | Form 4 ↗ |
| Feb 13, 2026 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 12,253 | $3.31 | $40.6K Sale | Form 4 ↗ |
| Feb 13, 2026 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 3,726 | $3.31 | $12.3K Sale | Form 4 ↗ |
| Feb 13, 2026 | Gaurav Shah CEO | RCKT Rocket Pharmaceuticals, Inc. | Sale | 12,279 | $3.31 | $40.6K Sale | Form 4 ↗ |
| Jan 2, 2026 | Elisabeth Bjork Director | RCKT Rocket Pharmaceuticals, Inc. | Buy | 10,000 | $3.44 | $34.4K Buy | Form 4 ↗ |
| Nov 18, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,086 | $2.98 | $3,236 Sale | Form 4 ↗ |
| Nov 18, 2025 | Jonathan David Schwartz See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 2,545 | $2.98 | $7,584 Sale | Form 4 ↗ |
| Nov 18, 2025 | Gaurav Shah CEO, Director | RCKT Rocket Pharmaceuticals, Inc. | Sale | 6,276 | $2.98 | $18.7K Sale | Form 4 ↗ |
| Nov 18, 2025 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,646 | $2.98 | $4,905 Sale | Form 4 ↗ |
| Oct 14, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 558 | $3.98 | $2,221 Sale | Form 4 ↗ |
| Oct 14, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 3,005 | $3.97 | $11.9K Sale | Form 4 ↗ |
| Oct 14, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 5,514 | $3.97 | $21.9K Sale | Form 4 ↗ |
| Oct 14, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 19,841 | $3.96 | $78.6K Sale | Form 4 ↗ |
| Aug 27, 2025 | Elisabeth Bjork Director | RCKT Rocket Pharmaceuticals, Inc. | Buy | 10,000 | $3.41 | $34.1K Buy | Form 4 ↗ |
| Aug 19, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 361 | $3.00 | $1,083 Sale | Form 4 ↗ |
| Aug 19, 2025 | Jonathan David Schwartz See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 805 | $3.00 | $2,415 Sale | Form 4 ↗ |
| Aug 19, 2025 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 588 | $3.00 | $1,764 Sale | Form 4 ↗ |
| Aug 18, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 699 | $3.07 | $2,146 Sale | Form 4 ↗ |
| Aug 18, 2025 | Jonathan David Schwartz See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,680 | $3.07 | $5,158 Sale | Form 4 ↗ |
| Aug 18, 2025 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,004 | $3.07 | $3,082 Sale | Form 4 ↗ |
| Aug 14, 2025 | Jonathan David Schwartz See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 11,161 | $3.02 | $33.7K Sale | Form 4 ↗ |
| Aug 14, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 7,043 | $3.02 | $21.3K Sale | Form 4 ↗ |
| Aug 14, 2025 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 12,109 | $3.02 | $36.6K Sale | Form 4 ↗ |
| Jul 3, 2025 | Aaron Ondrey Chief Financial Officer | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,477 | $2.88 | $4,254 Sale | Form 4 ↗ |
| May 20, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 357 | $6.45 | $2,303 Sale | Form 4 ↗ |
| May 20, 2025 | Jonathan David Schwartz See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 801 | $6.45 | $5,166 Sale | Form 4 ↗ |
| May 20, 2025 | Kinnari Patel See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 767 | $6.45 | $4,947 Sale | Form 4 ↗ |
| May 20, 2025 | Gaurav Shah CEO, Director | RCKT Rocket Pharmaceuticals, Inc. | Sale | 2,253 | $6.45 | $14.5K Sale | Form 4 ↗ |
| May 20, 2025 | Martin Wilson General Counsel | RCKT Rocket Pharmaceuticals, Inc. | Sale | 587 | $6.45 | $3,786 Sale | Form 4 ↗ |
| May 16, 2025 | John Militello See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 655 | $6.53 | $4,277 Sale | Form 4 ↗ |
| May 16, 2025 | Kinnari Patel See Remarks | RCKT Rocket Pharmaceuticals, Inc. | Sale | 1,409 | $6.53 | $9,201 Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:41 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances